Genes for which selections exist in E. coli and S. typhimurium
Gene;Organism;Selection;References;Alteration
ackA;E, S;Fluoroacetate resistance;96, 281, 463, 797;L
ada;E;Nitrosoguanidine resistance;693;
add;E;Deoxyadenosine + hypoxanthine satisfaction of purB requirement;370;L
add;S;Deoxyadenosine (low) satisfaction of purA requirement;326;L
adhCE;E;Chloracetaldehyde resistance;157;
adhCE;E;Chlorethanol resistance;157;
adhE;E;Allyl alcohol resistance;476;L
adh;E;Ethanol as C source;132;C
alaS;E;Thymineless death resistance in thyA;394;S
alaS;E;Mecillinam resistance (beta-lactam resistance);802;S
ampC;E;Ampicillin resistance;139, 570;D
ampC;E;Ampicillin resistance;210, 212, 362;C
amtAB;S;Aminotriazole resistance;828;
apeA;E, S;N-Acetyl-L-phenylalanine-β-naphthyl ester hydrolysis;421, 516;L
apt;E;6-Methylpurine resistance;60;L
apt;E;Adenine resistance in hpt gpt;462;
apt;E;2,6-Diaminopurine resistance in pnp;470;L
apt;E, S;2,6-Diaminopurine resistance;107, 390;L
araB;E;Ribitol resistance from araC(Con);396;L
araC;E;Fucose resistance (arabinose as C source);67;C
araC;E;Ribitol resistance from araC(Con);396;L
arcA;E;Male-specific phage resistance, also called fexA;110, 651, 711;L
argA;E;Acetylornithine + uracil satisfaction of car (pyrA);153;L
argB;E;N-Acetylhistidine + ornithine satisfaction of his;50;C
argB;E;Acetylornithine + uracil satisfaction of car (pyrA);153;L
argC;E;N-Acetylhistidine + ornithine satisfaction of his;50;C
argC;E;Acetylornithine + uracil satisfaction of car (pyrA);153;L
argD;E, S;Proline-independent growth of ∆proAB;62, 403;L
argD;E;Acetylornithine + uracil satisfaction of car (pyrA);153;L
argE;E;N-Acetylhistidine + ornithine satisfaction of his;50;C
argE;E;Acetylnorvaline resistance in argR(Con);402;L
argH;E;N-Acetylhistidine + ornithine satisfaction of his;50;C
argP;E;Canavanine resistance;483, 655;L
argP;E;Thiosine resistance;293, 716;L
argP;E;Canavanine + thiouracil resistance;605;L
argR;E, S;Arginine-resistant, proline-independent growth of ∆pro;62, 403;C
argR;E;Acetylhistidine satisfaction of his;49, 50, 403;C
argR;E;Acetylmethionine satisfaction of met;402;C
argR;E;Indospicine resistance;454;C
argR;E;Canavanine resistance;482, 523;C
argR;E;Glycylglycyl-N-phosphonoacetylornithine resistance;604;C
argR;E;Canavanine + azauracil resistance;605;C
argR;E;Canavanine + thiouracil resistance;605;C
argR;E;Acetylnorvaline resistance in argR(Con);402;
argS;E;Canavanine resistance;322;S
argS;E;Mecillinam resistance (beta-lactam resistance);802;S
argT;S;Hydrazino (α) imidazole propionic acid resistance;432, 433;
aroA;E, S;Glyphosate resistance;512, 731,869;C, D
aroF;E;Amino(4)phenylalanine resistance;504;C
aroF;S;Fluoro(4)phenylalanine resistance;270, 729;C
aroG;E, S;Methyl(3)anthranilate resistance;307;FBI, S
aroG;E;Thienylalanine resistance;215;FBI, S
aroG;E;Fluorophenylalanine resistance;351;FBI, S
aroH;E;Tryptophan analog resistance;637;FBI, S
aroP;E, S;Methyl(5)tryptophan resistance;12, 94, 288, 303, 393, 437-439;L, C
aroP;E, S;Fluoro(5)tryptophan resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Azaserine resistance;12, 94, 288, 303, 393, 437-439, 836, 837;L
aroP;E, S;Thienylalanine resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Fluorophenylalanine resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Azaleucine resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Methyl(5)tryptophan + thienylalanaine resistance;12, 94, 288, 303, 393, 437-439;L
aroT;E, S;Indole acrylic acid resistance;769;L
aroT;E;Methyl(4)tryptophan resistance in aroP;594;L
asm;S;Methionine sulfoxamine resistance;188;
atoB;S;Dinitropyrene resistance;590;L
atoC;E;Butyrate as C source in fadR(Con);602;C
atoC;E;Valerate as C source in fadR(Con);602;C
atoC;E;Penten(4)oate resistance in atoC(Con);669;L
atpA-atpE;E;Uncoupler resistances, including DCCD;225, 226, 229, 355, 537;L
atpA-atpE;E;Tributyl tin resistance;355;
atpA-atpE;E;CCCP resistance;355;
atpA-atpE;E;Pentachlorophenol resistance;355;
atpA-atpE;E;Auroventin resistance;451, 685, 818;L
atpA-atpE;E;Kanamycin resistance;768;L
atpA-atpE;E;Neomycin resistance;392;L
atpA-atpE;E;Azide resistance;355;
atr;S;Acid resistance;233;
azaAB;E;Azaserine resistance;836;
azl;E;Azaleucine resistance;610;
bglBC;E;Arbutin as C source;523, 616, 640;
bglBC;E;Salicin as C source;523, 616, 640;
bglT;E;Methyl(β)glucoside as C source;686;C
bio operon;E;Dehydrobiotin resistance;206;
bioP;E;Dehydrobiotin resistance;206;L
birA;E;Dehydrobiotin resistance;206, 597;
brnQ;E;Methyl(o)threonine resistance;278;L
brnQ;E;Valine resistance;277;L
btuB;E;Colicin E3 tolerance;46, 47, 109, 284, 388, 620;
btuB;E, S;Bf23 phage resistance;46, 47, 109, 284, 388, 528, 620;
bymA;E;Maltose utilization in malT;327;
cbt;E;Chloroacetate(β) resistance;68;L
cbt;E;Colicin B tolerance;623;L
cbt;E;Colicin D tolerance;623;L
cdd;E;Aza(5)-2′-deoxycytidine resistance;196;L
cdd;E, S;Fluoro(5)deoxycytidine resistance;53, 579;L
celABCDF;E;Cellobiose as C source;426;
cet;E;Colicin E2 tolerance;201;
che;S;Migration in a chemotaxis gradient;34;
chlABDEG;E, S;Chlorate resistance;2, 121, 122, 228, 266, 523, 743, 744;L
chlABDE;E;Lactate + fumarate as anaerobic energy source;436;L
chlC;S;Chlorate resistance;45;L
chlE;E;Lactate + nitrate as anaerobic energy source;799;
chlE;E;Biotin sulfoxide utilization in chl bio;180;
cirA;E;Colicin I resistance;77, 93, 620;L
cirA;E;Siderophore-beta-lactam conjugate resistance;93;L
cit;E;Citrate as C source;290;
cls;E;Dihydroxy(3,4)butyl-1-phosphonate resistance;345;L
cmlA;E;Chloramphenicol resistance;48;
cmlA;E;Tetracycline resistance;523, 638;
coaA;E;Coenzyme A feedback resistance;789, 790;FBI, S
codA(cod);E, S;Fluoro(5)cytosine resistance;4, 54;L
corABCD;E, S;Cobalt resistance;262, 600, 817;
corABCD;E;Manganese resistance;600;
corABCD;E;Nickel resistance;817;
cpd;S;Succinate as improved C source;8, 530;L
cpd;S;Citrate as C source in presence of low cAMP;8;L
cpdB;E;Fluorouracil(5) and 3′-AMP resistance;51;L
cpxA;E;Amikacin resistance;629;
cpxA;E;Colicin A tolerance;629;
cpxA;E;Kanamycin resistance;768;
cpxA;E;Q phage resistance;508, 711;
cpxA;E;Serine (L) as C source;567;
crg;E;Cold-resistant growth;398;
crp;S;Fosfomycin resistance;10;L
crp;E;Serine (L) resistance in relA;167;L
crp;E;Lambda phage + nalidixic acid resistance;429;L
crp;E;Streptomycin + cAMP resistance;31;L
crp;E;Lambda phage resistance with maltose and arabinose as C sources;92, 766;L
crp;E;cAMP + glucose 6-phosphate resistance;1a;L
crp;E;cAMP + glucose 6-phosphate + D-xylose + L-arabinose resistance;1a;L
crp;E;Fluorouracil(5) + 5′-AMP + 3′-AMP resistance;52;L
crp;E;Osmotolerance;282;L
crp;E;Beta-lactam resistance;362;L
crp;E;Mecillinam resistance;25, 168, 857;L
crp;E;UV light resistance;627;L
crp;E;Rifampin resistance;413;L
crp;E;T6 phage resistance;6;L
crr;E;Thio(5)glucose resistance;419;L
crr;S;Methylglucoside(α)-resistant utilization of glycerol in ptsHI;563;L
cxm;E;Xylose (D) + cAMP resistance;1a;L
cyaA;E;Lambda phage resistance with maltose and arabinose as C sources;92;L
cyaA;E;Lambda phage + nalidixic acid resistance;429;L
cyaA;E;Serine (L) resistance in relA;167;L
cyaA;S;Fosfomycin resistance;10;L
cyaA;E;Osmotolerance;282;L
cyaA;E;Beta-lactam resistance;362;L
cyaA;E;Mecillinam resistance;25, 168, 857;L
cyaA;E;UV light resistance;627;L
cyaA;E;Rifampin resistance;413;L
cyaA;E;T6 phage resistance;6;L
cycA;E;Cycloserine (D) resistance;150, 646, 813;L
cycA;E;Serine (D) resistance;689;L
cysA;S;Chromate resistance;581;L
cysA;E;Selenate resistance;728;L
cysA;S;Azaserine resistance;340, 689;L
cysB;S;Chromate resistance;340;L
cysB;S;Azide resistance;227;C
cysB;S;Selenate resistance;339;L
cysB;E;Novobiocin resistance;631;L
cysB;S;Triazole resistance;227;C
cysB;S;Azaserine resistance;340;L
cysC;S;Azaserine resistance;340;L
cysC;S;Chromate resistance;581;L
cysD;S;Azaserine resistance;340;L
cysD;S;Chromate resistance;581;L
cysE;S;Triazole resistance in cysM;717, 825;C
cysE;S;Triazole resistance;341;C
cysE;E;Novobiocin resistance;631;L
cysG;S;Azaserine resistance;340;L
cysH;S;Azaserine resistance;340;L
cysH;S;Chromate resistance;581;L
cysI;S;Azaserine resistance;340;L
cysI;S;Chromate resistance;581;L
cysJ;S;Azaserine resistance;340;L
cysJ;S;Chromate resistance;581;L
cysK;S, E;Azaserine resistance;340, 827;L
cysK;S;Azide resistance;147, 227;L
cysK;E;Selenate resistance;230;L
cysK;E, S;Triazole resistance;147, 227, 826, 827;L, C
cysK;E;Selenite resistance;230;L
cysL;S;Selenate resistance;673, 674;
cysL;S;Chromate + selenate resistance;338;
cysM;S;Azaserine resistance;340;L
cytR;E;Uridine as C source, improved utilization;546;
dadA;E, S;Chloro(β)-D-alanine resistance;832;L
dadA;E, S;D-Amino acid satisfaction of amino acid auxotrophy;428, 831;C
dcm;E;Aza(5)cytidine resistance;247;L
dct;E;Fluoro(3)malate resistance;401;L
dct;E;Tartrate resistance;687;L
dct;S;Malate (L) as improved C source;745;D
deoA;E;Deoxyadenosine + fluorouracil resistance in upp;3;L
deoA;E;Thymidine resistance in deoC;3;
deoB;E;Thymidine resistance in deoC;3, 651;L
deoB;E, S;Thymineless death prevention by low thymine levels in thyA;71, 471;
deoC;E;Thymineless death prevention by low thymine levels in thyA;325, 471, 651;L
deoD;E;Deoxy(2)adenosine resistance in deoC;651;L
deoD;E;Deoxyadenosine + fluorouracil resistance in upp;3;L
deoR;E;Inosine as improved C source;546;C
deoR;S;Diamino(2,6)purine satisfaction of purine auxotrophy;251;
deoR;S;Uridine resistance in thyA deoB;71;
dgd;E;Arabitol (D) as C source in fuc;849;
dgoR;E;Keto(2)-3-deoxygalactonate as C source;144;C
dgsA;E;Glucosamine as anaerobic C source in ptsG;652;L
dhuA;E, S;Histidine (D) satisfaction of his auxotrophs;422, 428, 546;
dhuA;S;Azaserine + tryptophan resistance;432;
dld;E;Vinylglycolate resistance;696;L
dml;S;Malate (D) as C source;737;
dnaB;E;Lambdoid phage mixture coinfection resistance;259;
dnaB;E;Phenethyl alcohol resistance;494;
dnaE;E;Acriflavin (acridine) resistance;553-555;
dnaE;E;Globomycin resistance;668;S
dnaJ;E;Lambda phage induction, resistance to;667;S
dnaJ;E;Lambdoid phage mixture coinfection resistance;257, 259;S
dnaJ;E;P2 phage + lambda phage coinfection resistance;753;S
dnaK;E;Lambda phage induction, resistance to;667;S
dnaK;E;Lambdoid phage mixture coinfection resistance;257, 259;S
dnaK;E;P2 phage + lambda phage coninfection resistance;753;S
dnaP;E;Phenethyl alcohol resistance;809;
dor;S;Drug-resistant gene maintenance;814;
dppA;E, S;Bacilysin resistance;1;L
dppA;E, S;Bialaphos resistance;1;L
dppA;E, S;Valine-containing dipeptide resistance;1;L
dppA;E;Lysyl-2-aminoxypropionate resistance;603;L
dppA;E;Glycylleucine resistance;269;L
dppA;E;Phenylalanylleucine resistance;269;L
dppA;E;Glycylvaline resistance in opp;178;L
dsdA;E;Sucrose as C source;5;L
dsdC;E;Sucrose as C source;5;
ebgA;E;Lactose utilization in ∆lacZ;118;Q
ecfB;E;Serine (L) as C source;567, 768;
ecfB;E;Kanamycin resistance;567, 768;
ecfB;E;Neomycin resistance;608;
ecfB;E;Colicin K resistance;608;
edd;E;Gluconate as C source in eda;239, 240;L
emrB;E;CCCP resistance due to gene dosage;472;D
emrB;E;Nalidixic acid resistance due to gene dosage;472;D
emrB;E;Thiolactomycin resistance due to gene dosage;250;D
emrB;E;Thiolactomycin resistance;250;
envB;E, S;Mecillinam resistance;359, 587;
envB;E;UV light resistance;24;
envM;E, S;Diazoborine resistance;63;S
envZ;E;Ampicillin resistance;362, 363;
envZ;E;Colicin L tolerance;812;
envZ;E;Lambda phage resistance;812;
envZ;E;Me1 phage resistance;801;
envZ;E;TPI phage resistance;812;
envZ;E;TuIa phage resistance;801;
envZ;E;Freeze-thaw resistance;112;
envZ;E;Colicin (multiple) resistance;626;
eryC;E;Erythromycin resistance;599;
eryD;E;Erythromycin resistance;830;
exbB;E;Albomycin resistance;205;
exbB;E;Colicin I resistance;283, 624;
exbB;E;Colicin (other) resistance;283, 624;
exbC;E;Colicin B resistance;624;
exbC;E;Colicin I resistance;283, 624;
exbC;E;Colicin (other) resistance;283, 624;
exuR;E;Aldohexuronate resistance in eda;612;
exuR;E;Hexuronate as C course in noninducible exuR eda;612;C
exuT;E;Aldohexuronate resistance in eda;612;L
fadB;E;Thiolactomycin resistance (due to gene dosage);778;D
fadL;E;T2 phage resistance in ompF+ or ompF;70, 534;L
fadR;E;Decanoate as C source;713;L
fba;E;Streptozotocin resistance;456;L
fepABCDG;E;Colicin B resistance;623, 624;L
fepABDCG;E;Colicin D resistance;623;L
fhuA;E, S;Albomycin resistance;87, 387, 388, 478,479;S
fhuA;S;ES18 phage resistance;87, 478, 479;S
fhuA;E;T1 phage resistance;93, 409,870;S, L
fhuA;E;T5 phage resistance;93, 151, 387,870;L
fhuA;E;Φ80 phage resistance;151, 387, 409,870;L, S
fhuA;E;Colicin M resistance;151, 387, 409;L, S
fhuA;E;Beta-lactam conjugate resistance;93;L
fhuB;E;Albomycin resistance;618;L
fliC;E, S;Chi phage resistance;347, 349, 416, 417, 513, 710;
fliC;S;Prolonged static cultivation;249;
flrB;S;Trifluoroleucine resistance;115, 117;
folA;E;Sulfonamide resistance;607, 697;S, D
folA;S;Trimethoprim resistance;405, 654, 718, 719;S, D
folP;E;Sulfonamide resistance;756;S
fruA;E;Deoxy(2)glucose-independent fructose utilization;11;
fruA;E;Xylitol resistance;614, 639;L
fruA;E;Sorbose (L) resistance;715;L
fts (generic);E;Filter retention;55;
ftsZ;E;UV irradiation resistance in lon;373;
ftsZ;E;Methyl methanesulfonate resistance in lon;373;
ftsZ;E;Nitrofurantoin resistance in lon;252;
fucA;E;Propanediol as C source;287;
fucA;E;Ethyleneglycol as C source in propanediol utilizer;79;
fucA;E;Fucose (L) as C source in propanediol utilizer;287;
fucA;E;Xylitol as C source in propanediol utilizer;848;
fucA;E;Arabinose (D) as C source;450;
fur;E;Manganese resistance;300;C
fusA;E;Fusidic acid resistance;65, 434, 695, 761;S
gabC;E;Aminobutyrate as N source;197;
gadS;E;Glutamate as C source;292;L
gal operon;E;Galactose utilization in the presence of thiomethylglucoside;636;D
gal operon;S;Deoxy(2)galactose resistance;9, 552;L
gal operon;E;Galactose resistance in galU;664;L
galC;S;Glucose as C source in ∆ptsHI;613;
galE;E, S;P1 phage infection of Salmonella sp. monitored by drug resistance;527;L
galE;E;U3 phage resistance;816;L
galE;S;Deoxy(2)galactose resistance;408;L
galE;S;Felix O phage resistance;334, 527, 591, 833;L
galE;S;P22 phage resistance;334, 527, 591, 833;L
galK;S;Deoxy(2)galactose resistance;408;L
galK;E, S;Galactose resistance in galE;569, 752;L
galK;E;Galactose resistance in galT;859;L
galK;E;Galactose resistance in galU;664;L
galP;S;Deoxy(2)galactose resistance;552;L
galR;E;Thiomethylgalactoside-independent utilization of galactose in galR(Con);108;
galR;S;Glucose utilization in ∆ptsHI;613;
galR;E;Galactose resistance in galT+K+E+/galT+K+E+ galU;664;
galT;E;Streptozotocin resistance;456;L
galU;E;Ampicillin resistance;212;L
galU;E;P1 phage resistance;242;L
galU;E;U3 phage resistance;816;L
galU;S;Felix O phage resistance;334;L
garA;S;Gamma irradiation resistance;346;
garA;E;Glucarate (D) resistance in ppc;647;L
garB;S;Gamma irradiation resistance;346;
gatACD;E;Fucitol resistance in galactitol-utilizing strains;184;L
gatACD;E;Deoxy(2)galactitol resistance in galactitol-utilizing strains;184;L
gatACD;E;Arabitol utilization;466, 845;
gatACD;E;Ribitol utilization;466, 845;
gatACD;E;Arbitol (D) resistance;639;L
gleR;S;Glycylleucine resistance in ilv;580;
glnA;S;Histidine(D) + glycylglutamine satisfaction of his auxotrophs;819;L
glnA;E;Methylammonium resistance;694;S
glnA;E;Methionine sulfoxamine resistance in glnG;592;C
glnA;S;Glutamyl(γ)hydrazide resistance;518,871;S
glnF;S;Glutamyl(γ)hydrazide resistance;433;L
glnH;S;Glutamyl(γ)hydrazide resistance;433;L
glnP;E;Glutamine as C source;433, 501, 820;
glnP;E, S;Methionine sulfoxamine resistance;37, 501;L
glnP;E;Glutamyl(γ)hydrazide resistance;501, 821;L
glnP;E;Glutamine (D) resistance;501;L
glnV;E;Caffeine resistance;185;S
glpD;E;Streptozotocin resistance;456;L
glpF;E;Glyceraldehyde (L) resistance;762;L
glpK;E;Glyceraldehyde (L) resistance;762;L
glpK;E, S;Methyl(α)glucoside-resistant glycerol utilization in ptsI;64, 665;
glpT;E, S;Fosfomycin resistance;10, 29, 313, 707, 800;L
glpT;E;Glyceraldehyde (DL) 3-phosphate resistance;762;L
glpT;E;Arsenate resistance;838;L
glpT;E;Dihydroxybutyl phosphonate resistance;285, 453;L
glpT;E;Fluorohydroxyacetone phosphate resistance;515;L
glpT;E;Chlorohydroxyacetone phosphate resistance;515;L
glpT;E;Glycerol 3-phosphorothioate resistance;295;L
gltA;E;Improved growth in icd;435;L
gltH;E;Glutamate as C source;496, 497, 687;
gltR;E;Glutamate as C source at 42°C;497;
gltS;E;Glutamate as C source;496, 687;Q
gltS;E;Glutamate as C source;496, 497, 687;
gltS;E;Glutamate (D) resistance in gltS (increased);525, 716;L
gltS;E;Methyl(α)glutamate resistance in gltS (increased);391, 525, 716;L
gltS;E;Homocysteic acid resistance;213;L
gltX;E;Glutamyl-γ-methyl ester resistance;425;
glyA;E;Serine + methionine + glycine resistance in relA;783;
gntM;E;Glycerol + gluconate as C source in eda;217;L
gntR;E;Acetate + gluconate as C source in ppc;39;
gntS;E;Acetate + gluconate as C source in ppc;39;L
gor;E;Methyl viologen tolerance;430;L
gprAB;E;Lambda phage resistance;578, 670;
gpt;S;Aza(8)guanine resistance;272, 764;L
gpt;E;Sulfanilamide resistance in presence of guanine;97;L
groM;E;T7 phage resistance;427;
grpD;E;Lambda mutant prophage induction, survival of;667;
grpE;E;Lambda mutant prophage induction, survival of;667;
gsh (generic);E;Nitrosoguanidine resistance;693;L
gsh (generic);E;Methylglyoxal resistance;548;
gshAB;E, S;Selenite resistance;423;L
guaAB;E;Psicofuranine resistance;779;
guaB;S;Fluoro(5)uracil + fluoro(5)uridine resistance;367;L
gurBCD;E;Glycerol + methylglucuronide a C source in eda;572;L
gyrA;E, S;Triazolealanine + aminotriazole resistance;660;S
gyrA;E, S;Nalidixic acid resistance;200, 298;S
gyrA;E;Quinolone resistance;860;S
gyrA;E;Oxolinic acid resistance;734;S
gyrA;E;Glucosides (β) as C source;194;
gyrA;S;Thermotolerance;200;
gyrB;S;Triaolealanine + aminotriazole resistance;660;S
gyrB;E;Aminotriazole resistance in relA;772;S
gyrB;E;Novobiocin resistance;255;S
gyrB;E;Coumermycin resistance;181, 255, 593;D, S
gyrB;E;Chlorobiocin resistance;589;
gyrB;E;Glucosides (β) as C source;194;
gyrB;E;Lambda mutant infection resistance;521;
gyrB;E;Nalidixic acid resistance;333, 855;S
hem;E;Streptomycin resistance;57;L
hemA;E;Kanamycin resistance;585;L
hemA;E, S;Neomycin resistance;683;L
hemB;E;Kanamycin resistance;585;L
hemB;E;Kanamycin-resistant, hemin-supported growth of hemA;507;L
hemB;E;Colicin K-type tolerance;83;
hemC;S;Neomycin resistance;682;L
hemD;S;Neomycin resistance;681;L
hemE;S;Neomycin resistance;189, 680;L
hemBCF;E;Plate method;506;L
hemG;E;Neomycin resistance;679;L
hemL;E;Kanamycin resistance;350;L
hflC;E;Lambda mutant phage resistance;56;
hflK;E;Lambda mutant phage resistance;56;
hflX;E;Lambda mutant phage resistance;56;
himA;E;Mu prophage induction, survival of;520, 522;
himA;E;Mu phage lytic growth resistance;81;
himA;E;Lambda mutant phage infection, survival of;519, 521;
himA (himC);E;Lambda mutant phage resistance;519, 521;
himD;E;Mu prophage induction, survival of;520, 522;
himD;E;Mu phage lytic growth resistance;81;
hipA;E;Cycloserine resistance;541;
hipA;E;Ampicillin resistance;541;
hipA;E;Fosfomycin resistance;541;
hipQ;E;Norfloxacin resistance;842;
hipQ;E;Ampicillin resistance;842;
his structural genes;E, S;Triazolealanine + aminotriazole resistance;98, 126, 658;C, Q
his structural genes;S;Aminotriazole resistance;20, 21;D
his structural genes;S;Growth at 42°C in his-overexpressing strain;804;Q
his structural genes;S;Histidinal satisfaction of his auxotroph requirement at 30°C;374, 375;Q
his structural genes;S;Histidine (D) satisfaction of his auxotroph requirement;374, 375;Q
hisG;E, S;Thiazolealanine resistance;540, 698, 824;S, FBI
hisG;S;Hydrazino (α) imidazole propionic acid resistance;699;S, FBI
hisG;S;Histidinal satisfaction of his auxotroph requirement at 30°C;374, 375;L
hisG;S;Histidine (D) satisfaction of his auxotroph requirement;374, 375;L
hisG;E;Histidine-resistant adenine → guanine nucleotide;33;S,FBI
hisJ;S;Hydrazino (α) imidazole propionic acid resistance;13, 15;L
hisJ;S;Azaserine + tryptophan resistance in dhuA;15, 432;
hisP;S;Hydrazino (α) imidazole propionic acid resistance in dhuA;14, 15;L
hisP;S;Arginine as N source;13, 15, 432;D
hisQ;S;Hydrazino (α) imidazole propionic acid resistance;13, 15;L
hisR;S;Triazolealanine + aminotriazole resistance;658;Q
hisR;S;Thiazolealanine resistance;706;Q
hisR;S;Methyl(2)histidine resistance + aminotriazole resistance;658;Q
hisS;S;Triazolealanine + aminotriazole resistance;658;S
hisS;S;Thiazolealanine resistance;657;S
hisT;E, S;Triazolealanine + aminotriazole resistance;98, 148, 658, 705, 784;L
hisT;E;Azaleucine resistance;98, 784;L
hisT;E;Serine resistance;98, 784;L
hisT;S;Amino(3)tyrosine resistance;148, 658, 705;L
hisT;S;Thialysine resistance;148, 658, 705;L
hisT;S;Trifluoroleucine resistance;148, 658, 705;L
hisT;S;Norleucine resistance;148, 658, 705;L
hisT;S;Hydroxy (β) leucine resistance;148, 658, 705;L
hisT;E;Phenyl galactoside resistance of lacP lacI (nonsense) supE;747;
hisU;S, E;Triazolealanine + aminotriazole resistance;23, 660;
hisU;S;Nalidixic acid resistance;593, 660;
hisW;S, E;Triazolealanine + aminotriazole resistance;23;
hisW;S;Coumermycin resistance;593, 660;
hpt;E;Mercapto(6)purine resistance in gpt;371;
hpt;E;Sulfanilamide + hypoxanthine resistance;97;L
hsd;E;Lambda vir resistance after infection with;183;L
hsd;S;Lactose utilization after conjugation of F′lac into Salmonella sp.;103;L
hut;S;Histidine as sole N or C source;509;
icdE;E, S;Nalidixic acid resistance;91, 311;L
iclR;E;Butyrate or valerate as better C source;602;C
iclR;E;Glucose or glycerol as C source in ppc;488;
ileR;E;Trifluoroleucine resistance;412;
ileS;E;Pseudomonic acid resistance;858;S
ileS;E;Thiaisoleucine resistance;757;S
ilv structural genes;S;Sulfometuron methyl + valine resistance;872;C
ilv structural genes;E;Aminobutyrate resistance;633, 780;C
ilv structural genes;E;Valine resistance;268;C
ilv structural genes;S;Cyclopentane glycine resistance;586;C
ilvA;S;Cyclopentane glycine resistance;586;S, FBI
ilvA;E;Glyclleucine resistance;806;S, FBI
ilvA;S;Threonine as sole N source;106;S, FBI
ilvA;E;Growth on minimal medium of ilvA+ (multicopy) ilvDC hisT overcoming 2-ketobutyrate accumulation;231;L
ilvB;E;Aminobutyrate resistance;633, 780;S, FBI
ilvB;E;Valine resistance;633, 755;S, FBI
ilvB;E;Glyclleucine resistance;269;S
ilvB;E;Phenylalanylleucine resistance;269;S
ilvF;E;Valine resistance;174, 610;G
ilvG;E, S;Sulfometuron methyl + valine resistance;441, 851,872;S, Q
ilvG;E;Valine resistance;221, 448, 720;G
ilvH;E;Aminobutyrate resistance;633, 780;S, FBI
ilvH;E;Valine resistance;633, 755;S, FBI
ilvH;E;Glyclleucine resistance;269;S
ilvH;E;Phenylalanylleucine resistance;269;S
ilvI;E;Aminobutyrate resistance;633, 780;S
ilvI;E;Valine resistance;633, 755;
ilvI;E;Glyclleucine resistance;269;
ilvI;E;Phenylalanylleucine resistance;269;
ilvJ;E;Valine resistance;174, 361, 649;G
ilvU;E;Thiaisoleucine resistance;222;
kdgR;E;Keto(2)-3-deoxygluconate as C source;377, 615;C
kdsA;S;9NA phage resistance in galE;452, 641;
ksgA;E;Kasugamycin resistance;312, 726, 793;L
ksgB;E;Kasugamycin resistance;238, 726;
ksgC;E;Kasugamycin resistance;861;
ksgD;E;Kasugamycin resistance;238;
lac;E;Growth in lactose-limited chemostats;330;D
lacI,operator;E;Methyl(α)glucoside-resistant utilization of lactose in ptsH;665;C
lacI,operator;E;Raffinose as C source;459;C
lacI,operator;E;Neolactose as C source;459;C
lacI,operator;E;Phenyl galactoside as C source;523;C
lacI,operator;E;Lactobionic acid as C source;440;C
lacI,operator;E;Lactitol as C source;457;C
lacI,operator;E;Melibiose as C source;475;C
lacIoperator;E;Melibiose as C source and acetyl(N)lactonate as N source;475;C
lacI,operator;E;Lactobionic acid as C source;474;
lacI,operator;E;Acetyl(N)lactonate as N source;474;Q
lacI,operator;E;Nitro(o)-phenylthiogalactoside resistance in lacI(Con) or lacO(Con);543, 571;Q
lacI,operator;E;Methyl(α)glucoside-resistant lactose utilization;406;C
lacY;E;Nitro(o)-phenylthiogalactoside resistance;523, 543, 721;L
lacY;E;Phenyl galactoside resistance;376;L
lacY;E;Phenethylyl galactoside resistance;376;L
lacY;E;Arabinose (L) growth in the presence of lac operon inducer;812;L
lacY;E;Thiodigalactoside resistance;241;
lacZ;E;Lactobionic acid as C source;440;D
lacZ;E;Phenyl galactoside resistance;376, 500;L
lacZ;E;Phenethylyl galactoside resistance;376, 500;L
lacZ;E;Nitro(o)-phenyl galactoside resistance;376, 500;L
lamB;E;Lambda phage resistance;88, 134, 135, 253, 644, 766;L, S
lamB;E;K10 phage resistance;644;
lamB;E;Thio(5)maltose resistance;223;L
lct;E;Vinylglycolate resistance;696;
leuA;S;Trifluoroleucine resistance;115;FBI, S
leuJ;E;Trifluoroleucine resistance;575;
leu(structural genes);S;Trifluoroleucine resistance;115, 116;C
leuS;S, E;Azaleucine resistance;477, 514;S
leuS;S;Trifluoroleucine resistance;7;S
leuW;E;Calmodulin inhibitor resistance;129;S
lev;E;Levallorphan resistance;164;
lexA;E;Mitomycin C resistance of recA (SOS-induced) sfi lexA3(Con);538;L
lig;E;T4 phage lig mutant nibbling of colonies yielding lig overproducer;254;Q
lig;E;T4 phage lig mutant resistance from lig overproducer;254;L
linB;E;Lincomycin resistance;26, 343;
lit;E;T4 mutant phage resistance;143;
livG;E;Azaleucine resistance;303, 561;L
livH;E;Valine resistance in leu;17, 595;L
livH;E;Azaleucine resistance;561;L
livJ;E;Valine resistance in leu;17, 595;L
livK;E;Valine resistance in leu;17, 595;L
lon;E, S;Chlorpromazine resistance;198, 529;L
lon;E;Promethazine resistance;529;L
lpp;E;Globomycin resistance;140, 344, 854, 868;L
lpcA;E;T3 phage resistance;792;L
lpcA;E;T4 phage resistance;792;L
lpcA;E;T7 phage resistance;792;L
lpcA;E;P1 phage resistance;40, 41;
lpcB;E;T4 phage resistance;760;
lpcB;E;T7 phage resistance;760;
lrp;E;Leucine (D) satisfaction of leu auxotrophs;18, 428;
lysC;E;Aminoethylcysteine (thialysine) resistance;82, 765;S, FBI
lysC;E;Lysine hydroxamate resistance;82, 765;S, FBI
lysP;E;Aminoethylcysteine (thialysine) resistance;611, 736;L
lysS;E;Aminoethylcysteine (thialysine) resistance;323;S
lysS;E;Phenyl galactoside resistance of lacI q lacI(nonsense) lacP supL;748;
lyt;E;Beta-lactam tolerance;700;
mac;E;Erythromycin growth dependence;725;
malE;E, S;Methylglucoside(α)-resistant utilization of maltose;665;
malE;E;Thio(5)maltose resistance;223;L
malF;E, S;Methylglucoside(α)-resistant utilization of maltose;665;
malF;E;Thio(5)maltose resistance;223;L
malG;E, S;Methylglucoside(α)-resistant utilization of maltose;665;
malG;E;Thio(5)maltose resistance;223;L
malK;E;Lambda phage resistance;766;L
malK;E, S;Methylglucoside(α)-resistant utilization of maltose;177, 665;
malK;E;Thio(5)maltose resistance;223;L
malP;E;Maltose as C source in malT;327;
malQ;E;Maltose as C source in malT;327;
malT;E;Lambda phage resistance;766;L
malT;E;Thiomaltose resistance;223;L
manA;E;Streptozotocin resistance;456;
manC;E;Lyxose (D) as C source;738;
manXYZ;E;Phage N4 resistance;410;
manXYZ;E;Deoxyglucose resistance;158, 379;L
marA;E;Menadionine resistance;274;
marA;E;Chloramphenicol resistance;286;
marA;E;Tetracycline resistance;286, 329;
mbrABCD;E;Camphor resistance;776, 777;
mdoB;E;Arbutin resistance in dgk;360;L
mel (generic);E;Raffinose as C source in lacI;459;
mel (generic);S;Methylglucoside(α)-resistant utilization of melibiose;665;
melB;E;Deoxy(2)glucose-resistant utilization of melibiose;431;S
melB;E;Lithium-resistant utilization of melibiose;397;S
metA;S;Methyl(α)methionine resistance;127, 447;FBI, S
metC (ecfA?);E;Neomycin resistance;464;
metC (ecfA?);E;Colicin K resistance;465;
metC (ecfA?);E;Chloro(β)alanine resistance;832;
metG;E;Ethionine resistance;28;S
metJ;E, S;Ethionine resistance;447;
metJ;E;Glutamyl-γ-methyl ester resistance;425;S
metJ;E, S;Norleucine resistance;128;
metJ;E;Methionine sulfoximine + methyl(α)methionine resistance;386;S
metK;E, S;Ethionine resistance;275, 289, 447, 735;S
metK;E;Glutamyl-γ-methyl ester resistance;425;S
metK;E, S;Norleucine resistance;128, 447, 735;S
metK;S;Methyl(α)methionine resistance;447, 735;S
metL;E;Hydroxy (β) norvaline resistance;138;S, FBI
metPD;E, S;Methyl(α)methionine resistance;37, 38, 386;L
metPD;E, S;Methionine sulfoximine resistance;37, 38, 386;L
mglA;E;Fucose + arabinose-supported growth in galP;209, 613;
mglB;E;Fucose + arabinose-supported growth in galP;209, 613;
mglC;E;Fucose + arabinose-supported growth in galP;209, 613;
mglD;E;Methyl-β-galactoside-supported growth;645;C
mng;E;Manganese resistance;708;
mopA;E;T4 phage resistance;258;S
mopB;E;T4 phage resistance;258;S
motAB;E;Chi phage resistance;349, 709, 710;
mrb;E;Fosfomycin resistance;800;
mrdA;E;Mecillinam resistance;759;
mrdB;E;Mecillinam resistance;358, 502, 759;
mreBCD;E;Mecillinam resistance;582, 807;
mtlA;E;Arabinitol (D) resistance;614;L
mtlC;E;Mannitol (limiting) as C source;722;C
mtr;E;Methyl(5)tryptophan resistance;305, 320, 523;L
murZ;E;Fosfomycin resistance due to increased gene dosage;499;D
mut (generic);E;Streptomycin resistance;309;
mut (generic);E;Azaserine resistance;703;
mut (generic);E;Chemostat growth;152;
mutH;E;Amino(2)purine resistance in dam;267;L
mutL;E;Amino(2)purine resistance in dam;267;L
mutS;E;Amino(2)purine resistance in dam;267;L
mvrC;E;Methyl viologen resistance;532;D
nadB;S;Amino(6)nicotinamide resistance;142, 336;S
nadD;S;Amino(6)nicotinamide resistance;336, 337;L
nagA;E;Streptozotocin resistance;456;L
nagA;E;Iodoacetylglucosamine resistance;823;L
nagB;E;Iodoacetylglucosamine resistance;823;L
nagE;E;Streptozotocin resistance;456;L
nagE;E;Iodoacetylglucosamine resistance;823;L
nagE;E;Deoxy(2)-2-iodoacetamideoglucose resistance;379;L
nalB;E;Nalidixic acid resistance;298;
nalD;E;Nalidixic acid resistance;333;
nar (general);E;Metronidazole resistance;677;L
narC;E;Chlorate resistance;266, 280;L
narG;E;Chlorate resistance;739;L
narH;E;Chlorate resistance;739;L
ndk;S;Aza(8)guanine resistance;264, 650;
neaB;E, S;Neamine resistance;119, 182, 495;
nek;E;Aminoglycoside resistance;27, 342;
nfnA;E;Nitrofurantoin resistance;684;
nfnB;E;Nitrofurantoin resistance;684;
nfsA;E;Nitrofuranzone resistance;90, 505;
nfsB;E;Nitrofuranzone resistance;90, 505;
nhaA;E;Lithium resistance (multicopy);628;D
nol;S;Norleucine resistance;324;
nov;E;Novobiocin resistance;630;
nrdA;E;Hydroxyurea resistance;609;D
nrdB;E;Hydroxyurea resistance;609;D
nupC;E;Showdomycin resistance;415, 545;L
nupC;E;Fluorouracil resistance;544;L
nupC;E;Fluorodeoxyuridine resistance;545;L
nupC;E;Fluoruridine resistance;544;L
nupC;E;Fluorodeoxycytidine resistance;544;L
nupG;E;Fluorouracil resistance;544;L
nupG;E;Fluorodeoxyuridine resistance;545;L
nupG;E;Fluorouridine resistance;544;L
nupG;E;Fluorodeoxycytidine resistance;544;L
nusA;E;Lambda prophage induction, survival of;244;
nusB;E;Lambda prophage induction, survival of;245, 260;
nusB;E;Lambdoid phage resistance;260;
nuvA;E, S;Near-UV irradiation resistance;424, 468, 767;L
nuvC;E;Near-UV irradiation resistance;663;
ompA;E;K3 phage resistance;306, 489, 491, 493;L
ompA;E;T-even-like phage resistance;199, 533, 535;S
ompA;E;TuII* phage resistance;171, 314, 493;L
ompA;E;Ox2 phage resistance;199, 493, 642;
ompA;E;Bacteriocin JF246 resistance;124, 491;
ompA;S;Bacteriocin 4-59 resistance;741;L
ompA;E;Colicin K tolerance;491;
ompA;E;Colicin L tolerance;491;
ompA;E;Chelator resistance;493;
ompA;E;Novobiocin resistance;493;
ompB;S;PH51 phage resistance;372;
ompB;S;PH105 phage resistance;372;
ompC;E;Me1 phage resistance;791, 801;L
ompC;E;TuIa phage resistance;801;L
ompC;S;PH51 phage resistance;372;L
ompC;S;PH105 phage resistance;372;L
ompC;E;Host range Serratia marcescens phage resistance;702;
ompD;S;PH51 phage resistance;741;L
ompD;S;Bacteriocin 4-59 resistance;741;L
ompF;E;Beta-lactam (ampicillin, cefoxitin) resistance;362, 363;L
ompF;E;Chloramphenicol resistance;235, 523;L
ompF;E;Tetracycline resistance;235, 523;L
ompF;E;Fluoro(5)uracil + nucleotide resistance;52;L
ompF;E;Colicin A tolerance;125, 235;
ompF;E;Cloacin DF13 resistance;846;L
ompF;E;Colicin L tolerance;235, 291;L
ompF;E;Colicin K tolerance;235;L
ompF;E;Colicin E2 tolerance;235;
ompF;E;Colicin E3 tolerance;235;
ompF;E;Me1 phage resistance;801;L
ompF;E;TuIa phage resistance;801;L
ompF;E;TuIb phage resistance;237;
ompF;S;PH51 phage resistance;372;L
ompF;S;PH105 phage resistance;372;L
ompF;E;Copper resistance in ompC;480;
ompR;E;Me1 phage resistance;801;
ompR;E;TuIa phage resistance;801;
ompR;E;Copper resistance;52, 625;
ompR;E;Beta-lactam (ampicillin, cefoxitin) resistance;362, 363;L
ompR;E;Chloramphenicol resistance;625;
ompR;E;Fluoro(5)uracil + nucleotide resistance;52;
oppA;E, S;Triornithine resistance;43, 317;L
oppA;E;Glycylleucine resistance;806;L
oppA;E;Alanyl-2-aminopropionate resistance;603;L
oppA;E, S;Trilysine resistance;317;L
oppA;E, S;Norleucylglycyl glycine resistance;317;L
oppA;S;Glycylglycyl histidinol phosphate ester resistance;317;L
oppA;E, S;Phaseolotoxin resistance;733;L
oppA;E;Tripeptide (toxic amino acid containing) resistance;604;L
oppA;E;Glycylglycyl-N-S-(phosphonoacetyl)-L-ornithine resistance;604;L
oppE;E;Tripeptide (toxic amino acid containing) resistance;22;L
optA;E;T7 phage gene 1.2 mutant resistance;666;
osmB;E;Osmotolerance;384;L
osmZ;E;Arbutin as C source;179;
osmZ;E;Salicin as C source;179;
oxyR;E, S;Peroxide resistance;131;C
pab;E;Sulfonamide resistance;97;C
pan;E;Salicylate resistance;481;C
pan;E;Hydroxyaspartate resistance;701;C
pan;E;Pentylpantothenamide resistance;136;C
pdx;E;Isoniazid resistance;186;C
pepA;S;Alafosfalin resistance;263;L
pepA;E, S;Peptide (toxic, valine containing) resistance in pepN;517;L
pepD;E, S;Peptide (toxic, valine containing) resistance in pepN pepA;517;L
pepN;E, S;Albomycin resistance;86;L
pepN;E, S;Peptide (toxic, valine containing) resistance;517;L
pepN;E, S;Indicator plate;445;
pepQ;E, S;Peptide (toxic, valine containing) resistance;517;L
pfkA;E;Streptozotocin resistance;456;L
pgi;E;U3 phage resistance;816;L
pgi;E;Fosfomycin + fructose-6-phosphate resistance;243;L
pgm;E;U3 phage resistance;816;L
pheA;E;Fluoro(4)phenylalanine resistance;351, 564;C, FBI
pheR;S;Fluoro(4)phenylalanine resistance;271;C
pheS;E;Fluoro(4)phenylalanine resistance;78, 218, 395;S
pheS;E;Thymineless death resistance in thyA;394;S
pheU;S;Fluoro(4)phenylalanine resistance;729;
pho;S;Glycerol(β)-phosphate as C source in the presence of high phosphate;407;C
phoA;E;Fluoro(5)uracil + adenosine resistance in upp, phoS, or phoT;315;
phoA;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;773;C
phoA;E;Glycerol(β)-phosphate resistance in glpD;678;
phoB;E;Tellurite resistance;770;
phoB;E;TC45 phage resistance;771;L
phoB;E;Fluoro(5)uracil + adenosine resistance in upp, phoS, or phoT;316;
phoE;E;Acid resistance;659;D
phoE;E;TC45 phage resistance;420, 771;S, L
phoR;E;Arsenate resistance;852;
phoR;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;204, 838;
phoR;E;TC45 phage resistance;621;S
phoS;E;Arsenate resistance;852;
phoS;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;204, 838;
phoS;E;TC45 phage resistance;621;S
phoT;E;Arsenate resistance;852;
phoT;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;204, 838;
phoT;E;TC45 phage resistance;621;S
phr;E;T1 phage (UV irradiated) resistance;332;L
phxB;E;φX174 phage resistance;547;L
pit;E;Arsenate resistance;59, 727;L
pldA;E;Actinomycin D resistance in the presence of EDTA;301, 805;L
pmi;S;P22 phage resistance;656, 833;L
pmi;S;9NA phage resistance;656, 833;L
pmrA;E, S;Polymyxin resistance;219, 297, 485, 785-788;
pmrA;S;Neutrophil granule protein resistance;219;
pncA;E, S;Amino(6)nicotinamide resistance;234, 455, 822;L
pncA;E;Nicotinamide as sole N source;598;Q
pncB;E, S;Amino(6)nicotinamide resistance;234, 455;L
pncB;E, S;Amino(6)nicotinate resistance;234, 455;L
pncX;S;Amino(6)nicotinamide resistance;336;
pnp;E;Showdomycin resistance;58;
polA;E;Lambda γ mutant phage resistance;867;L
praA,B;S;P221 phage resistance;576, 674;L
praA,B;S;PH51 phage resistance;576;L
praA,B;S;PH105 phage resistance;576;L
prbA,B;S;ES18 phage resistance;674;
prdB;S;PH51 phage resistance;674;
prfA;E;Phenylgalactoside resistance of lacP lacI(nonsense) supE;747;
prfB;E;Negamycin resistance;145;
prh;S;HK009 phage resistance;674;
prk;S;HK068 phage resistance;674;
proAB;S;Osmotolerance;155;
proA;E;Nitro(4)pyridine N-oxide resistance;62, 222, 321;L
proB;E, S;Dehydroproline resistance;62, 155, 635;FBI, S
proB;E;Nitro(4)pyridine N-oxide resistance;62, 222, 321;
proB;E, S;Azetidine carboxylate resistance;62, 155, 635;FBI, S
proP;E, S;Dehydroproline resistance in putA putP;156, 732;L
proU;S;Dehydroproline + azetidine carboxylate resistance at high osmolarity in putA putP;156;L
prp;E;Propionate as C source;400;Q
pspABCDE;E;Sulfanilamide + hypoxanthine resistance;97;
pss;E;Ethanol resistance;133;
pss;E;Dimethyl sulfoxide resistance;133;
pstABCS;E;Arsenate resistance;727, 838;L
pstABCS;E;TC45 phage resistance;621;S
pta;S;Fluoroacetate resistance;96, 281, 463, 797;
pts (general);E;Glucose + gluconate-independent motility;30;
ptsG;E;Methyl(α)-glucoside resistance;102, 104;
ptsG;E;Sorbose resistance;715;L
ptsG;E, S;Deoxy(2)glucose-independent utilization of fructose;418, 510;L
ptsG;E, S;Deoxy(3)-3-fluoroglucose-independent utilization of fructose;418, 510;L
ptsG;E;Methyl(α)-glucoside-independent lactose + mannitol utilization;80;L
ptsG;E;Glucosamine as C source;379;
ptsG;E;Mannose as C source;379;
ptsHI;E, S;Deoxy(3)-3-fluoroglucose-independent utilization of lactate;510;L
ptsHI;E, S;Fosfomycin resistance;146, 800;L
ptsHI;E;Streptozotocin resistance;16,873;L
ptsI;E;Ampicillin resistance;212;
ptsI;S;Deoxy(3)-3-fluoroglucose resistance;510;L
purA;E;Methyl(6)purine + hypoxanthine resistance;60;
purB;E;Nalidixic acid resistance;310;L
purR;E;Adenine resistance in hpt gpt;461, 462;
putA;E, S;Azetidine carboxylic acid resistance;511, 635, 775;L
putAP;S;Baikiain resistance in constitutive background;187;L
putA;S;Proline as N source with glucose as C source;566;
putP;E, S;Dehydroproline resistance;193, 511, 635, 732, 775, 843;L
putP;E, S;Azetidine carboxylic acid resistance;193, 511, 635, 775, 843;L
putP;S;Lithium-resistant proline utilization as C source;551;S
puvA;E;Psoralen + UV irradiation resistance;328;C
pyrB;S;Arginine-independent growth of pyrH in the presence of uracil;366;L
pyrC;S;Arginine-independent growth of pyrH in the presence of uracil;366;L
pyrD;S;Arginine-independent growth of pyrH in the presence of uracil;366;L
pyrF;E;Fluoro(5)orotic acid resistance;74;L
pyrH;S;Fluoro(5)orotic acid resistance;865;C
pyrH;S;Fluorouracil resistance;385;C
pyrH;S;Fluorouridine resistance;385;C
pyrH;E;Fluoro(5)uracil + 5-fluorouridine resistance in udp;606;
qmeACDE;E;Glycine tolerance;829;
rap;E;Lambda phage resistance;279;
recA;E;Lambda prophage induction deficiency during thymine deprivation;190;
recF;E;Thymineless death resistance in thyA;558;
recJ;E;Thymineless death resistance in thyA;558;
recO;E;Thymineless death resistance in thyA;558;
recQ;E;Thymineless death resistance in thyA;557;
relA;E;UV (near) irradiation resistance;632;L
relA;E;Serine resistance in relA;167;
rep;E;P2 phage resistance;113;
rfa (general);E, S;U3 and FO phage resistance;35, 484, 486, 588, 833;
rfa (general);E, S;Ampicillin resistance;212, 550, 562;
rfa (general);S;Hemin satisfaction of hemA auxotrophy;364;
rfa (general);S;Cephalothin resistance;562;
rfa (general);S;Bacitracin resistance;562;
rfaCDEF;S;FO phage resistance;676;
rfaD;E;C21 phage resistance;141;
rfaD;E;P1 phage resistance;141;
rfaH;S;FO phage resistance;458, 675;
rfaP;E;U3 phage + K3 phage coresistance;601;
rfb;S;DCCD resistance in rfa;833;
rho;E;T4 phage resistance;740;
rho;E;Lambda sus N7 nin-5 resistance in P2 lysogen;352, 353;
rho;E, S;Polarity suppression of gal leader insertion;169, 331;
ridA;E;Rifampin + kasugamycin dependence;162;
ridB;E;Rifampin dependence;160;
rplC;E;Tiamulin resistance;73;
rplD;E;Erythromycin resistance;725, 840;S
rplE;E;Thiopeptin resistance;467;
rplF;E;Gentamicin resistance;101;S
rplK;E;Kasugamycin resistance;159;
rplK;E;DAP starvation of ∆(mal-asd) in the presence of serine, methionine, and glycine;165;
rplN;E;Kasugamycin resistance;159;
rplN;E;Lincomycin resistance;343;
rplO;E;Lincomycin resistance;343;
rplV;E;Erythromycin resistance;840;
rpoA;E;P2 vir1 phage resistance;754;S
rpoB;E;Lambda cII + rifampin coresistance;296;S
rpoB;E;Streptovaricin resistance;863;S
rpoB;E;Rifampin resistance;216, 359, 369;S
rpoB;E;Streptolydigin resistance;357, 469, 688;S
rpoB;S;Fluorouracil resistance;368;S
rpoB;E;Lambda phage + 434 phage cross-resistance;256;S
rpoB;E;Lambda Nmar mutant phage resistance;261;S
rpoB;E;Serine resistance in relA;784;S
rpoB;E;Rifampin resistance in rpoB+/rpoB (rif) merodiploids;36;L
rpoB;E;T7 phage resistance;690;S
rpoC;E;T7 phage gene 2 resistance;100;
rpoD;E;Lambda cI71 resistance;556;
rpoD;E;Arabinose (L) as C source in cya or crp;712;S
rpoH;E;Temperature resistance in rpoD(Ts);577;S
rpsB;E;Kasugamycin resistance;583, 861;S
rpsB;E;Cold resistance in rpsE cold-sensitive mutants;559;
rpsC;E;Spectinomycin resistance and sucrose dependence;195;S
rpsD;E;Spectinomycin resistance and sucrose dependence;195;S
rpsD;E;Streptomycin independence of streptomycin-dependent rpsL;304;
rpsE;E;Spectinomycin resistance and sucrose dependence;195, 526;S
rpsE;E, S;Spectinomycin resistance;172, 495, 634, 672, 853;S
rpsE;E;Streptomycin independence of streptomycin-dependent rpsL;304;
rpsG;E;Lincomycin resistance;343;S
rpsI;E;Kasugamycin resistance and dependence;161, 163;S
rpsJ;E;Lambda prophage induction, resistance to;170, 246;S
rpsL;E, S;Streptomycin resistance;89, 495, 853;S
rpsL;E;Neamine dependence;798;
rpsL;E;Paromomycin resistance or dependence;853;S
rpsL;E;Phenyl galactoside resistance of lacP lacI (nonsense) supE;747;
rpsM;E;Kasugamycin resistance;159;
rpsQ;E;Neamine resistance;76, 119;S
rpsR;E;Kasugamycin resistance;159;
rrn;E;Erythromycin resistance;704;S
rrn;E;Chloramphenicol resistance;704;S
rrn;E;Spectinomycin resistance;704;S
sbaA;E;Serine resistance;166;
sbmA;E;Microcin B17 resistance;446;
sdh;E;Succinate-independent growth in lpd;154;
secA;E, S;Azide resistance;227, 232, 584, 808, 864;
secA;E;Phenethyl alcohol resistance;808, 864;
semA;E;Microcin E492 resistance;622;
serA;E;Serine hydroxamate resistance;774;FBI, S
serS;E;Serine hydroxamate resistance;774;S
sidCF;S;Albomycin resistance;87, 478, 479, 674;
sidK;S;Albomycin resistance;87, 478, 479, 674;
sidK;S;ES18 phage resistance;87, 478, 479, 674;
sloB;E;Nalidixic acid tolerance;473;
sloB;E;Amidinopenicillin tolerance;473;
sorAT;E;Sorbose (L) as C source in crosses with wild strains;844;
spcB;S;Spectinomycin resistance;853;
srlA;E;Sorbitol + xylitol resistance;639;L
srlD;E;Fructose as C source in ptsF or ptsM;378;
sspA;E;P1 phage resistance;835;L
strB;S;Streptomycin resistance;273, 853;
strC;S;Streptomycin resistance;648;
strM;E;Streptomycin resistance;671;
strM;E;Phenyl galactoside resistance of lacIq lacI(nonsense) lacP supL;748;
sulA;E;UV irradiation resistance in lon;373;L
sulA;E;Methyl methanesulfonate resistance in lon;373;L
sulA;E;Nitrofurantoin resistance in lon;252;L
tabC;E;T4 phage resistance;258;
tct;S;Fluorocitrate resistance;724;L
tct;S;Trifluorocitrate resistance;723;L
tct;S;2-Fluoro-L-erythrocitrate resistance;32;L
tdk;E, S;Azidothymidine resistance;207;L
tdk;S;Fluorodeoxyuridine + uracil resistance in deoA;54;
tdk;E;Fluoro(5)deoxyuridine resistance;749;L
tdk;E;Bromo(5)deoxyuridine + UV irradiation resistance;319, 348;L
tet;E, S;Fusaric acid resistance;72, 487;L
tet;S;Quinaldic acid resistance;72;L
thdA;E;Dapsone resistance;383;
thi;E;Pyrithiamine resistance;399;C
thrA;E, S;Thialysine resistance;365;S, FBI
thrA;E;Serine resistance;294;S, FBI
thrABC;E;Amino(2)-hydroxy(3)-pentoate resistance;847;D
thrS;E;Borrelidin resistance;248, 276, 560, 596;S, Q
thyA;E, S;Aminopterin resistance;66, 123, 325, 730;L
thyA;E;Trimethoprim resistance;66, 730;L
tinA (tlr);E, S;Thiolutin resistance;381, 382, 714;
tmk;E;Dideoxy(2′,3′)thymidine resistance;176;S
tnaA;E;Tryptophan-supported growth at 13°C;568;C
tna;E;Indole + methyl(5)tryptophan-supported, glucose-resistant growth in ∆trp;862;
tol;E;Bacteriocin tolerance;85, 120, 173, 236;
tolQAB;E;Colicin E1 resistance;449;
tolQAB;E;TuIa phage resistance;449;
tolB;E;Colicin E resistance;19;L
tolB;E;Azaleucine resistance;19;L
tolC;E;Colicin E1 tolerance;536, 653;L
tolD;E;Colicin E2 and E3 tolerance;210;
tolD;E;Ampicillin resistance;105, 210;
tolE;E;Colicin E2 and E3 tolerance;210, 211;
tolE;E;Ampicillin resistance;210, 211;
tolI;E;Colicin Ia and Ib tolerance;120;
tolJ;E;Colicin L, A, and S4 tolerance;173;
tolM;E;Colicin M tolerance;302;
tolQ;E;Colicin group A tolerance;84a, 750;
tolQ;E;Filamentous phage tolerance;84a, 750;
tolR;E;Colicin group A tolerance;84a, 750;
tolR;E;Filamentous phage tolerance;84a, 750, 751;
tolZ;E;Colicin E2, E3, D, 1a, and 1b tolerance;503;
tonB;S;ES18 phage resistance;149, 741;
tonB;E;T1 phage resistance;46;
tonB;E;φ80 phage resistance;46;
tonB;E;Colicin B resistance;46, 623;
tonB;E, S;Albomycin resistance;85, 505, 741;
tonB;E;Colicin M resistance;85, 523;
tonB;S;Bacteriocin 4-59 resistance;741;
tonB;E;Cephalosporin E-0702 resistance;815;
topA;S;Kanamycin resistance;202;
topA;S;Neomycin resistance;202;
topA;S;Streptomycin resistance;202;
tpp;E;Alafosfalin resistance;603;L
tpp;E;Triornithine resistance in opp;44;L
tppA;S;Tripeptide (toxic) resistance;263;
tppB;S;Tripeptide (toxic) resistance;263;
trmE?;E;Phenyl galactoside resistance of laclq lacI(nonsense) lacP supL;748;
trp (generic);E, S;Fluoro(6)tryptophan resistance;42, 318;C
trp (generic);E, S;Methyl(5)tryptophan resistance;42, 318;C
trpE;E, S;Methyl(5)tryptophan resistance;114, 539;S, FBI
trpE;E;Methyl(3)anthranilate resistance;308;S, FBI
trpR;E, S;Methyl(5)tryptophan resistance;42, 137, 523, 746;
trpR;E;Chuangxinmycin resistance;850;
trpS;E;Indolmycin resistance;75;D
trxA;E;T7 phage resistance;498;L
trzA;S;Triazole resistance;339;
tsx;E;T6 phage resistance;99, 299, 490, 492, 620;L, S
tsx;E;Colicin K resistance;99, 299, 490, 492, 620;L, S
tsx;E;Albicidin resistance;69;
tufAB;E;Kirromycin resistance;220, 356, 763, 795;
tufAB;E, S;Mocimycin resistance;335, 794;
tyn;S;Tyramine as N source;549;
tyrA;E, S;Fluorophenylalanine resistance;270, 729;C
tyrA;E;Amino(4)phenylalanine resistance;504;C
tyrR;E, S;Amino(4)phenylalanine resistance;95, 504, 811;
tyrR;E;Fluorotyrosine resistance;130;
tyrR;S;Fluoro(4)phenylalanine resistance;729;
tyrS;E;Fluorotyrosine resistance;662;S
ubi (generic);E;Neomycin resistance;265;L
ubiF;S;Fluoro(5)uracil + carbamylaspartate resistance;404, 866;L
ubiF;E;Gentamicin resistance;542;
ubiF;E;Streptomycin resistance;542;
udhA;S;Fluoro(5)uridine resistance;834;L
udk;E;Fluoro(5)uridine + uracil resistance;380;L
udk;E;Fluoro(5)uridine resistance in upp;565;L
udp;E;Fluoro(5)uracil + adenosine resistance;606, 617;L
ugpAB;E;Fluorohydroxyacetone phosphate resistance;515;L
ugpAB;E;Dihydroxybutylphosphonate resistance in glpT;691, 692;L
ugpAB;E;Glycerol-3-phosphate as C source in glpT;691;C
uhpR;E;Glucosamine 6-phosphate as C source;191;C
uhpR;S;Glucose 1-phosphate as C source;192;C
uhpR;E;Fructose 1-phosphate as C source;224;C
uhpT;E;Chloro-3-hydroxyacetone resistance in uhp(Con);515;L
uhpT;E;Fluoro-3-hydroxyacetone resistance in uhp(Con);515;L
uhpT;E;Dihydroxybutylphosphonate resistance in uhp(Con);285;L
uhpT;E;Hydroxybutylphosphonate resistance in ubp(Con);285;L
uhpT;E;Deoxydihydroxyphosphonyl methyl fructose resistance;285;L
uhpT;E;L-Glyceraldehyde-3-phosphate resistance in uhp(Con);285;L
uhpT;E;Fosfomycin resistance;230, 389, 800;L
uhpT;E;Deoxy(2)glucose-6-phosphate resistance;214;L
uidA;E;Galacturonide as C source;742;C
uidA;E;Methylgalacturonide as C source;573;C
uidA;E;Methylglucuronide + glycerol-supported growth in eda;572;L
uidR;E;Galacturonide as C source;742;C
uidR;E;Methylgalacturonide as C source;573;C
ung;E;Bromodeoxyuridine + UV light resistance;856;L
ung;E;T4 phage (uracil containing) resistance;203;L
upp;E, S;Fluoro(5)uracil resistance;53, 605, 617;L
upp;E;Aza(6)uracil resistance;605, 617;L
upp;E;Canavanine + aza(6)uracil resistance;605, 617;L
ushA;E;Fluoro(5)uracil + 5′-AMP resistance in upp;52;L
uvrA;E;UV-irradiated lytic phage resistance;332;
uvrB;E;UV-irradiated lytic phage resistance;332;
uvrC;E;UV-irradiated lytic phage resistance;332;
uvrD;E;UV-irradiated lytic phage resistance;332;
uxaBC;E;Hexuronate resistance in eda;742;L
uxuAB;E;Hexuronate resistance in eda;742;L
uxuR;E;Methylgalacturonide as C source;574;C
valS;E;Thymineless death resistance in thyA;394;S
xapA;E;Fluoro(5)uracil + adenosine resistance in upp deoD xapR(Con);111;L
xapR;E;Adenosine as C source in upp deoD;111;C
xapR;E;Inosine as C source in upp deoD;111;C
xylE;E;Xylose resistance in fda;175;L